Volume 31, Number 2—February 2025
Research Letter
Sin Nombre Virus as Unlikely Reverse Zoonotic Threat
Table
Results of experimental inoculation using deer mice in a study of SNV as an unlikely reverse zoonotic threat*
Sample ID | Original infected sample |
Experimental infection of deer mice |
|||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Origin | qRT-PCR, relative Ct value† |
Serology, endpoint titer‡ |
qRT-PCR, positive/total samples† |
Serology, endpoint IgG titer§ |
|||||||||
Blood | BAL, others | IgM | IgG | Lung | Liver | Spleen | Kidney | Blood | |||||
HAN67/23 | Human | 22.9 | SNS | >6,400 | – | 0/3 | NA | NA | NA | 0/3 | 3/3 (100) | ||
HAN79/23 | Human | 25.0 | 29.2 | 1,600 | – | 0/3 | NA | NA | NA | 0/3 | 2/3 (100–1,600) | ||
HAN124/23 | Human | 31.5 | 28.4 | >6,400 | – | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 4/4 (400–1,600) | ||
HAN126/23 | Human | + | SNS | 1,600 | – | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 4/4 (100–400) | ||
HAN238/23 | Human | + | SNS | 1,600 | 400 | 0/3 | 0/3 | 0/3 | 0/3 | 0/3 | N/A | ||
HAN018/21 | Human | 28.0 | SNS | 400 | – | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 4/4 (100–400) | ||
HAN176/22 | Human | 25.0 | SNS | 1,600 | – | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 4/4 (400–1,600) | ||
HAN173/23 | Human | + | 29.5 | >6,400 | – | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 4/4 (100–1,600) | ||
HAN194/23 | Human | 27.7 | SNS | 1,600 | 400 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 4/4 (400–1,600) | ||
HAN266/23 | Human | 28.1 | SNS | >6,400 | 100 | 1/4 | 1/4 | 0/4 | 0/4 | 0/4 | 4/4 (100–400) | ||
Total human samples |
1/37 |
1/31 |
0/31 |
0/31 |
0/37 |
33/34 |
|||||||
EC983 | NHP | 24.3 | 27.1 | 1,600 | 1,600 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 6/6 (100–1,600) | ||
MB1599 | NHP | 23.4 | 27.2 | 400 | 800 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 4/4 (400) | ||
EC1545 | NHP | 24.1 | 28.5 | 3,200 | 1,600 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 3/4 (100–400) | ||
MB1291 | NHP | 25.6 | >35 | 400 | 400 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 4/4 (100–400) | ||
NV1021 | NHP | 24.0 | 30.5 | 800 | 800 | 0/4 | 0/4 | 0/4 | 0/4 | 0/4 | 4/4 (100–400) | ||
Total NHP samples |
0/22 |
0/22 |
0/22 |
0/22 |
0/22 |
21/22 |
|||||||
Vero-adapted SNV 77734 | VCL prep 1 | NA | 22.0 | NA | NA | 3/3 | 2/3 | 3/3 | 3/3 | 2/3 | NA | ||
VCL prep 2 | NA | 17.5 | NA | NA | 4/4 | 3/4 | 4/4 | 4/4 | 0/4 | 4/4 (>6,400) | |||
Total Vero samples |
7/7 | 5/7 | 7/7 | 7/7 | 2/7 | 4/4 |
*Deer mice (Peromyscus maniculatus) were inoculated with specimens from SNV-infected humans, cynomolgus macaques (Macaca fascicularis), and Vero cells. Endpoint titers are measured in reciprocal serum dilution. BAL, bronchoalveolar lavage; Ct, cycle threshold; NA, not available; NHP, nonhuman primate; OD, optical density; qRT-PCR, qualitative reverse transcription PCR; SNS, sample not submitted; SNV, Sin Nombre virus; VCL, Vero cell line; +, RT-PCR–positive sample but Ct value not available; –, not detected. †qRT-PCR threshold: Ct <35. ‡Seropositivity threshold: >0.6 net OD405. §Seropositivity threshold: mean OD650 from negative control + 3 SD (Appendix).
1Current affiliation: Vaccine and Infectious Disease Organization, Saskatoon, Saskatchewan, Canada.